The Keto Diet and Cancer: Is Metabolism not Genetics The Key? | In Vivo w/ Dr. Tomas Duraj | Ep. 23
In VivoShow Notes
In this episode of In Vivo, we sit down with Dr. Tomás Duraj to challenge a century of conventional wisdom about cancer. For decades, the dominant theory has been the somatic mutation theory, which suggests cancer is a genetic disease caused by random mutations.Dr. Duraj and his colleagues are proposing a paradigm shift, viewing cancer as a mitochondrial metabolic disease. This theory explains that cancer cells are fundamentally different from healthy cells in how they produce energy, relying on a less efficient form of energy production through glucose and glutamine fermentation. This metabolic inflexibility is what makes them vulnerable.We discuss the history of cancer research, the flaws in the current paradigm, and the exciting potential of a new approach: Ketogenic Metabolic Therapy (KMT). Dr. Duraj explains how KMT, which includes a ketogenic diet, is not just a diet but a comprehensive strategy to create a metabolic disadvantage for cancer cells while protecting and empowering healthy ones.We cover:The Warburg Effect and the metabolic theory of cancerThe difference between how healthy cells and cancer cells generate ATPHow a ketogenic diet and other therapies can synergistically target cancer's vulnerabilitiesThe potential of KMT in treating aggressive cancers like glioblastomaThis is a must-watch for anyone interested in a new perspective on cancer research and treatment.Connect with Dr. Tomás Duraj: http://www.tomasduraj.com/Dr. Duraj's 2024 paper on KMT: https://pubmed.ncbi.nlm.nih.gov/39639257/In Vivo on X - https://x.com/InVivoPodOnXIn Vivo on Youtube - https://www.youtube.com/@InVivoPodcastIn Vivo on Apple Podcast - https://podcasts.apple.com/us/podcast/in-vivo/id1775578563In Vivo on Amazon Podcasts - https://music.amazon.ca/podcasts/1ac4dbec-df46-4d1f-b0a1-742e9656ef44/in-vivo
More from In Vivo
Philosopher and historian of science Dr. Justin Garson joins me to unpack The Madness Pill: One Doctor’s Quest to Understand Schizophrenia, the mid-century hunt for a pill that could temporarily induce schizophrenia so scientists could reverse-engineer a cure.
Dr. Jason Kelly, co-founder and CEO of Ginkgo Bioworks, joins me to unpack autonomous labs, what they are, why biology’s bench tooling barely moved in 20 years, and why the right analogy isn’t a subway or a car, but a Waymo. Is the biology singularity around the corner?
Cathy Tie (founder, Origin Genomics) and Prof. Jiang Xueqin (Predictive History) join me for a wide-open conversation on germline gene editing, the science, the ethics, and the geopolitics.
Jason Verbelli, founder of Galilean Variance and CEO/Lead Engineer at SEG Magnetics, argues that Einstein left a written test for his own theory: if the speed of light depends even a little on the motion of the source, relativity and Einstein’s theory of gravitation are false. In this interview we start from first principles and work up through John Searl, magnetic waveforms, free energy vs over-unity, the double-slit experiments, the Casimir effect, and what that would mean for energy, technology, and space travel.
In this episode of In Vivo, I sit down with Dr. Rasmus Rosenberg Larsen, Assistant Professor of Forensic Epistemology at the University of Toronto and author of Psychopathy Unmasked: The Rise and Fall of a Dangerous Diagnosis (MIT Press).